Clinical Trials Browser

INDUSTRY × brexucabtagene autoleucel × Clear all

NCT05041309 2026-05-14

Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells

Enrolling by invitation

1,000 enrolled

Other hematologic neoplasm

Hematologic Neoplasms

NCT02625480 2026-04-09

ZUMA-4

Phase 1/2 Completed

95 enrolled

Lymphoid

Recurrence, Lymphoma, B-Cell

NCT05776134 2026-04-08

Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene Autoleucel

Available

LymphoidOther hematologic neoplasm

Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02601313 2026-03-18

ZUMA-2

Phase 2 Completed

105 enrolled 33 charts 1 FDA

Lymphoid

Lymphoma, Mantle-Cell

NCT05537766 2026-03-10

ZUMA-25

Phase 2 Terminated

19 enrolled 28 charts

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Leukemia, Hairy Cell, Waldenstrom Macroglobulinemia, Recurrence

NCT06253663 2025-12-16

JKART-1

Phase 2 Active not recruiting

25 enrolled

Lymphoid

Recurrence, Lymphoma, Mantle-Cell

NCT04880434 2025-11-17

ZUMA-2

Phase 2 Completed

95 enrolled

Lymphoid

Lymphoma, Mantle-Cell

NCT02614066 2024-11-19

ZUMA-3

Phase 1/2 Completed

125 enrolled 27 charts 1 FDA

Recurrence

NCT03624036 2023-11-18

ZUMA-8

Phase 1 Terminated

16 enrolled 17 charts

LymphoidOther hematologic neoplasm

Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT04162756 2021-10-14

ZUMA-18

Approved for marketing

Lymphoid

Recurrence, Lymphoma, Mantle-Cell